NCT00793793 - Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 25, 2011

Conditions

Hepatitis C, Chronic

Interventions

DRUG

BI201335

patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days

DRUG

BI201335

patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days

DRUG

BI201335

patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days

DRUG

BI201335

patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days

DRUG

Placebo

Trial Locations (16)

1220.2.10 Boehringer Ingelheim Investigational Site, San Francisco

1220.2.15 Boehringer Ingelheim Investigational Site, San Francisco

1220.2.17 Boehringer Ingelheim Investigational Site, Baltimore

1220.2.11 Boehringer Ingelheim Investigational Site, New York

1220.2.12 Boehringer Ingelheim Investigational Site, New York

1220.2.14 Boehringer Ingelheim Investigational Site, Austin

1220.2.3304A Boehringer Ingelheim Investigational Site, Lyon

1220.2.3303A Boehringer Ingelheim Investigational Site, Marseille

1220.2.3301A Boehringer Ingelheim Investigational Site, Paris

1220.2.3302A Boehringer Ingelheim Investigational Site, Paris

1220.2.49002 Boehringer Ingelheim Investigational Site, Berlin

1220.2.49005 Boehringer Ingelheim Investigational Site, Düsseldorf

1220.2.49006 Boehringer Ingelheim Investigational Site, Hanover

1220.2.49004 Boehringer Ingelheim Investigational Site, Kiel

1220.2.49003 Boehringer Ingelheim Investigational Site, Mainz

1220.2.34001 Boehringer Ingelheim Investigational Site, Madrid